// App-Quantinova.ai

P550 : A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)

Researchers

Presenter

  • Naval G Daver

Principal Investigators

  • Ke Liu

  • Scott Werneke

  • Evelyn Rustia

  • Paresh Vyas

Medical Centers

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Gilead Sciences, Inc.,Foster City,Stati Uniti

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Medicine,University of Oxford Radcliffe,Oxford,Reino Unido

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Gilead Sciences, Inc.,Foster City,Vereinigte Staaten

  • Gilead Scie

  • Department of Medicine,University of Oxford Radcliffe,Oxford,Reino Unido

  • Department of Medicine,University of Oxford Radcliffe,Oxford,Reino Unido

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Medicine, T

  • The University of Texas MD Anderson Cancer...

  • Gilead Sciences, Inc.,Foster City,Vereinigte Staaten

  • Gilead Sciences, Inc.,Foster City,Stati Uniti

  • Department of Medicine,University of Oxford Radcliffe,Oxford,Reino Unido

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • Department of Leukemia,University of Texas MD Anderson Cancer Center,Houston,Vereinigte Staaten

  • Department of Medicine,University of Oxford Radcliffe,Oxford,Reino Unido

  • Gilead Sciences, Inc.,Foster City,Stati Uniti

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT05079230

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved